Given the involvement of the cGAS‐STING pathway in inflammation, senescence and disease, inhibitors of cGAS (Lama et al., 2019) or STING (Haag et al., 2018) could potentially be used to treat age‐related chronic inflammation in A‐T patients. Here, STING1 is linked to inflammation.